Loading market movers...

JNT-517 Tablet

Phase 3

00%

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Nov '26

OTSKFPhase 3$34.0B

✓Positive

JNT-517 Tablet Phase 3 Est. Readout

JNT-517 Tablet• Phenylketonuria (PKU)120

Nov 2026~Confirmed

Competitive Landscape

0 competitors in Phenylketonuria (PKU)

View Full Landscape

Drug Information

Target Indication

Phenylketonuria (PKU)

Clinical Trial

Last updated: 12/30/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

OTSKF

OTSUKA

Healthcare•North America•NASDAQ

Related Pipeline

ProbucolPhase 3

Hyperlipidemia

EB-1020 (Centanafadine) 328.8 mgPhase 3

Attention Deficit Hyperactivity Disorder (ADHD)

Brexpiprazole, OPC-34712Phase 3

Agitation Associated With

centanafadine capsulePhase 3

Attention Deficit/Hyperactivity Disorder

Centanafadine HydrochloridePhase 3

Attention-Deficit/Hyperactivity Disorder

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts